This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NVRO Stock Declines Despite Positive Study Data of Nevro1 System
by Zacks Equity Research
Nevro unveils publication of positive data study regarding its Nevro1 SI Joint Fusion System.
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now
by Zacks Equity Research
WST continues to gain momentum due to its strength in the Pharma market unit. However, decline across its Generics and Biologics business units is concerning.
Reasons to Retain BSX Stock in Your Portfolio for Now
by Zacks Equity Research
Investors remain optimistic about Boston Scientific due to its geographical expansions and impressive acquisitions.
BSX Stock Gains From Positive OPTION Trial Data for WATCHMAN FLX
by Zacks Equity Research
Boston Scientific announces favorable OPTION trial results for its WATCHMAN FLX LAAC device. In terms of stroke risk reduction, WATCHMAN FLX is found to be superior to OAC therapy.
Boston Scientific Stock Set to Gain From Completion of Axonics Deal
by Zacks Equity Research
BSX's acquisition of Axonics marks its entry into sacral neuromodulation and complements its Urology business.
INBS Stock Declines Despite Positive Results of Pharmacokinetic Study
by Zacks Equity Research
Intelligent Bio Solutions unveils strong initial results for its PK study, which is important for FDA submission of its Intelligent Fingerprinting Drug Screening System.
LivaNova's OSPREY Sleep Apnea Trail on aura6000 Meets Primary Endpoint
by Zacks Equity Research
LIVN's aura6000 significantly increases responder rates. The device also reduces AHI and ODI levels. A premarket approval application will be filed soon.
Here's Why You Should Add OMCL Stock to Your Portfolio Now
by Zacks Equity Research
A robust Advanced Services portfolio and long-term growth initiatives bode well for Omnicell.
EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test
by Zacks Equity Research
Exact Sciences presents new positive evidence backing the development of an MCED test.
Globus Medical (GMED) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Add RMD Stock to Your Portfolio Now
by Zacks Equity Research
Robust Mask and Device sales bode well for ResMed. Meanwhile, the increasing debt burden adds to the worry.
Nevro Stock May Gain on the CE Mark Certification for HFX iQ
by Zacks Equity Research
NVRO's HFX iQ SCS system receives CE Mark Certification in Europe. Nevro expects to begin launching HFX iQ in select European countries from the first quarter of 2025.
GE HealthCare and DeepHealth Collaborate to Advance AI in Imaging
by Zacks Equity Research
GEHC and DeepHealth collaborate to develop AI-based imaging tools that can streamline workflow and help manage large imaging volumes without compromising diagnostic accuracy.
SOLV Stock Falls Despite Launch of Clarity Precision Grip Attachments
by Zacks Equity Research
Solventum's Clarity precision grip attachments enhance treatment outcomes for orthodontic patients, reducing the risk of misplaced and malformed attachments.
Why Globus Medical (GMED) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
MYGN Stock Might Gain From SneakPeek Availability in Retail Stores
by Zacks Equity Research
Myriad Genetics announces the availability of SneakPeek - the first at-home early fetal sex test in Walmart, Walgreens and CVS stores nationwide.
Here's Why You Should Add HealthEquity Stock to Your Portfolio Now
by Zacks Equity Research
HQY's sustained strength in HSAs raises optimism about the stock.
IART Stock to Gain From New Study Findings on DuraSeal Dural Sealant
by Zacks Equity Research
According to a health economic evaluation, Integra's DuraSeal Dural Sealant is revealed to reduce healthcare costs.
Is Globus Medical (GMED) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Globus Medical (GMED) possesses solid growth attributes, which could help it handily outperform the market.
QGEN Collaborates With McGill University Centre: Stock to Gain?
by Zacks Equity Research
QIAGEN joins forces with McGill University Centre for Microbiome Research to generate evidence-based knowledge for medicine and public health.
Expanding Global Market, NuVasive Benefits to Aid GMED Stock
by Zacks Equity Research
Globus Medical is seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
Labcorp Adds New Capabilities to Global Trial Connect: Stock to Gain?
by Zacks Equity Research
LH launches new enhancements to Global Trial Connect to streamline site workflow.
Reasons to Retain Veeva Systems Stock in Your Portfolio Now
by Zacks Equity Research
VEEV's robust product portfolio raises optimism about the stock. However, stiff competition and escalating costs are concerning.
GMED or SONVY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GMED vs. SONVY: Which Stock Is the Better Value Option?
ZBH Stock to Gain Support From Market Share Gains Amid Macro Issues
by Zacks Equity Research
Zimmer Biomet expects ROSA and Persona Cementless Knee to enhance its robotics and cementless market penetration to 50% to 60% range at a rapid pace.